AI-09 In Subjects With Glabellar Lines, GL-101
- Registration Number
- NCT05565950
- Lead Sponsor
- Eirion Therapeutics Inc.
- Brief Summary
AI-09 In Subjects with Glabellar Lines
- Detailed Description
A Phase 1/2, multicenter, out-patient, prospectively randomized, double-blind, vehicle-controlled study to establish an initial therapeutic range for AI-09 in the treatment of glabellar lines and provide initial data regarding its potential safety.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 72
Inclusion Criteria
- able to understand and give written informed consent
- willingness to have their pictures taken
- 20 - 70 years of age
- moderate to severe glabellar lines (IGA 2-3) on contraction
- moderate to severe glabellar lines (SSA 2-3) on contraction
- none to mild glabellar lines wrinkles (IGA 0-1) at rest
- willingness to refrain from the use of facial fillers, retinoids, Botox, laser treatments, or any product affecting skin remodeling or that might cause an active dermal response during the course of the study
- female subjects of child-bearing potential must have a negative urine pregnancy test and be non-lactating at the Baseline visit
- female subjects of child-bearing potential must utilize one of the following methods of birth control throughout the study: IUD, diaphragm, a condom, a spermicidal gel or foam, oral contraceptives (provided subject has been utilizing this method for at least 4 months prior to Baseline and has not changed the brand within this period), or patch, injectable, implantable, or vaginal ring contraceptives. Subjects may also participate if they are surgically sterilized (tubal sterilization or hysterectomy)
- subjects should be in good general health as determined by the investigator and free of any disease that may interfere with study evaluations or the Investigational Product
Exclusion Criteria
- the inability to substantially lessen glabellar lines by physically spreading them apart
- excessive weakness or atrophy in the target muscle(s)
- eyelid ptosis
- presence or history of "dry eye"
- history of periocular surgery, brow lift or related procedures, or deep dermal scarring
- concurrent or recent (within the last 6 months) use of any other botulinum toxin drug product anywhere in the body
- history of immunization or hypersensitivity to any botulinum toxin serotype
- history of non-response to any prior botulinum toxin treatments
- anticipated need for treatment with botulinum toxin of any serotype for a reason during the trial (other than the investigational treatment)
- any medical condition that may put the subject at increased risk with exposure to botulinum toxin including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function
- pregnancy or lactation
- application of any topical prescription medication to the treatment area within 14 days prior to treatment
- subjects on clinically significant, concomitant drug therapy
- participation in another investigational drug trial or receiving any investigational treatment(s) within 30 days of Baseline
- alcohol or drug abuse within the past 3 years
- psychiatric disease interfering with the subject's ability to give informed consent
- refusal or inability to comply with the requirements of the protocol for any reason
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Vehicle Dose 2 Vehicle Vehicle, intramuscular injection, administered once at baseline Vehicle Dose 3 Vehicle Vehicle, intramuscular injection, administered once at baseline Vehicle Dose 1 Vehicle Vehicle, intramuscular injection, administered once at baseline Vehicle Dose 5 Vehicle Vehicle, intramuscular injection, administered once at baseline Vehicle Dose 7 Vehicle Vehicle, intramuscular injection, administered once at baseline AI-09 Dose 3 AI-09 Dose 3 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline AI-09 Dose 5 AI-09 Dose 5 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline AI-09 Dose 1 AI-09 Dose 1 of botulinum toxin, Type A, intramuscular injection, administered once at baseline Vehicle Dose 4 Vehicle Vehicle, intramuscular injection, administered once at baseline Vehicle Dose 6 Vehicle Vehicle, intramuscular injection, administered once at baseline AI-09 Dose 7 AI-09 Dose 7 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline AI-09 Dose 2 AI-09 Dose 2 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline AI-09 Dose 6 AI-09 Dose 6 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline AI-09 Dose 4 AI-09 Dose 4 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline
- Primary Outcome Measures
Name Time Method Investigators Global Assessment (IGA) 18 Weeks (26 Weeks for Cohorts 4, 5 & 6) Investigators Global Assessment. Glabellar Line Severity scale where severity is scored between 0-4 (0=absent; 4=severe).
- Secondary Outcome Measures
Name Time Method Total Number of Observations With a Response Defined as Change ≥2 in IGA-C and SSA-C Score Week 1, 2, 4, 8, 12, 18 (Week 26 assessments for Cohorts 4, 5 & 6) Total number of observations with a change in the Investigators Global Assessment on Contraction, IGA-C, and the Subject Self-Assessment on Contraction, SSA-C, using the Glabellar Line Severity scale (GLS), where severity is scored between 0-4 (0=absent; 4=severe). To count, a "responder" is defined as a change by at least two ordinals in both assessments.
Trial Locations
- Locations (1)
Eirion Research Site
🇺🇸Miami, Florida, United States